A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2018
At a glance
- Drugs Nitric oxide (Primary)
- Indications Atopic dermatitis
- Focus Biomarker; Pharmacokinetics
- Sponsors Novan Inc
- 11 Dec 2018 According to a Novan media release, data from this trial will be presented at the 3rd Inflammatory Skin Disease Summit in Vienna, Austria.
- 06 Sep 2018 Status changed from active, no longer recruiting to completed.
- 20 Aug 2018 According to a Novan media release, data will be submitted for presentation by Drs. Guttman and Maeda-Chubachi at upcoming scientific and medical meetings.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History